FDA – Page 4 – Policy & Medicine

FDA: Off Label May Be the Wrong Label

IOM: Evaluation of Biomarkers and Surrogate Endpoints in Chronic Disease

FDA Transparency Initiative: Draft Disclosure Policies

Astra Zeneca Seroquel Settlement and Corporate Integrity Agreement

Building a Comparative FDA May Not Lead to Effectiveness

FDA Educates Industry on Development of Orphan Drugs

GAO Recommends the FDA to Strengthen Investigation Oversight

Fox Stossel Show: Hands Off My Healthcare

Letters from Grassley: FDA to Clarify Policies on Medical Devices

Five Part Podcast Series on FDA Features John Kamp of Coalition for Healthcare Communication